Results 181 to 190 of about 201,578 (196)

A one‐year efficacy assessment of subcutaneous immunotherapy in dust mite allergic rhinitis patients based on clinical symptoms and objective biomarkers

Eye &ENT Research, EarlyView.
Abstract Objective To evaluate the 1‐year efficacy of subcutaneous immunotherapy (SCIT) in treating dust mite‐induced allergic rhinitis (AR) and establish objective biomarkers for efficacy monitoring. Methods Fifty‐nine AR patients underwent 1‐year SCIT. Subjective symptoms were assessed via total nasal symptom score (TNSS), combined symptom/medication
Jingwen Wang, Xu Xu, Xu Zhang, Yuan Zhang, Jingyun Li   +4 more
wiley   +1 more source

Advances in locally administered nucleic acid therapeutics. [PDF]

Bioact Mater
Shen J, Duan X, Xie T, Zhang X, Cai Y, Pan J, Zhang X, Sun X.   +7 more
europepmc   +1 more source

Percutaneous mechanical circulatory support for acute right heart failure: A practical approach

ESC Heart Failure, EarlyView.
This is an overview of percutaneous mechanical circulatory support options for acute right heart failure, illustrating key clinical scenarios, device types, and principles of tailored device selection based on haemodynamics and underlying pathology. Abstract Acute right heart failure (RHF) represents a critical entity with significant morbidity and ...
Mario Gramegna, Christophe Vandenbriele, Guido Tavazzi, Mir B. Basir, Caroline Bleakley, Mario Iannaccone, Daniel Kretzschmar, Francesco Maisano, Anna Mara Scandroglio, Benedikt Schrage, P. Christian Schultze, Gregory Serrao, Matthew Tomey, Richard Trimlett, Dirk Westermann, Matteo Montorfano, George Dangas, Susanna Price, Alaide Chieffo   +18 more
wiley   +1 more source

Improving patient access to symptomatic treatment through self-serving nausea stations at Peace Arch Hospital emergency department. [PDF]

BMJ Open Qual
Samra I, Manes A, Dragoman R, Behboudi A, Grosu B.   +4 more
europepmc   +1 more source

Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology

European Journal of Heart Failure, EarlyView.
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a ...
Maurizio Volterrani, Geza Halasz, Stamatis Adamopoulos, Pier Giuseppe Agostoni, Javed Butler, Andrew J.S. Coats, Alan Cohen‐Solal, Wolfram Doehner, Gerasimos Filippatos, Ewa Jankowska, Carolyn S.P. Lam, Ekaterini Lambrinou, Lars H. Lund, Giuseppe Rosano, Marco Metra, Stefania Paolillo, Pasquale Perrone Filardi, Amina Rakisheva, Gianluigi Savarese, Petar Seferovic, Carlo Gabriele Tocchetti, Massimo Piepoli   +21 more
wiley   +1 more source

Bronchopleural fistula secondary to smoke inhalation injury: a case report. [PDF]

J Med Case Rep
Zahid I, Tahir R, Sohail A, Hooks BJ.
europepmc   +1 more source

Interpretation of in vitro concentration‐response data for risk assessment and regulatory decision‐making: Report from the 2022 IWGT quantitative analysis expert working group meeting

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Quantitative risk assessments of chemicals are routinely performed using in vivo data from rodents; however, there is growing recognition that non‐animal approaches can be human‐relevant alternatives. There is an urgent need to build confidence in non‐animal alternatives given the international support to reduce the use of animals in toxicity ...
Marc A. Beal, Guangchao Chen, Kerry L. Dearfield, Min Gi, Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Alexandra S. Long, David P. Lovell, Barbara L. Parsons, Stefan Pfuhler, John Wills, Andreas Zeller, George Johnson, Paul A. White   +14 more
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Role and mechanism of molecular hydrogen in the treatment of Parkinson's diseases. [PDF]

Front Neurosci
Wang F, Zhang G, Zhai Q.
europepmc   +1 more source

A Novel Method for Preparing Uniform Micro-Sized Dry Powder Formulations, Including Aggregation-Controlled VHH. [PDF]

Antibodies (Basel)
Moritani T, Masaki H, Yonehara R, Suzuki T, Arai H, Tsuchiya M, Nemoto N.   +6 more
europepmc   +1 more source